U.S. Biosimilars Market | 2021 Size, Growth, Share, Cap, Regional Analysis With Global Industry Forecast To 2027, is latest report on Global “U.S. Biosimilars Industry”, published by “Fortune Business Insights”. According to this report Global U.S. Biosimilars Market to rise at healthy Compound Annual Growth Rate and will reach USD 17,696.0 Mn by 2027. U.S. Biosimilars Market for U.S. Biosimilar is Segmented by Size, Share & COVID-19 Impact Analysis, By Drug Class (Filgrastim & Pegfilgrastim, Monoclonal Antibodies and Others), By Disease Indication (Caner, Auto Immune Diseases (Arthritis, Psoriasis, Neutropenia, and others), and Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2020-2027
Leading Players operating in the U.S. Biosimilars Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Hoffmann-La Roche Ltd.,
- AbbVie Inc.,
- Merck & Co.,
- Celltrion Inc.,
- Coherus BioSciences, Inc.,
- Teva Pharmaceutical Industries Ltd.,
- Eli Lilly and Company
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990
The report covers:
- Global U.S. Biosimilars Market trends, with detailed analysis on consumer trends & manufacturer trends.
- Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
- Key areas of investments identifying market opportunities and challenges in forecast timeframe.
- Competitive analysis of the industry players along with the overview on strategic management.
- Comprehensive company profiles of the major industry players.
Pfizer Inc., Samsung Bioepis Co. Ltd., and Other Key Players Tend to Focus on Product Launch to Strengthen Position
Samsung Bioepis Co. Ltd, a biopharmaceutical company, received approval from Food and Drugs Administrations for ETICOVO, a biosimilar of Etanercept in April 2019. It is used for the treatment of plaque psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, and psoriatic arthritis. Pfizer Inc. a multinational pharmaceutical company based in the U.S., received approval from FDA for TRAZIMERA, a biosimilar referencing Herceptin in March 2019. It will be used to treat gastroesophageal junction adenocarcinoma and breast cancer. Earlier in July 2018, Pfizer Inc. announced that the company has received FDA approval for NIVESTYM. It is a biosimilar to Neupogen that is approved to treat neutropenia. The FDA also granted approval for Truxima, the first biosimilar of rituximab in November 2018. It is developed by Celltrion Inc., a biopharmaceutical company headquartered in South Korea, for the treatment of non-Hodgkin’s lymphoma.
Increased Research and Development Initiatives to Drive the Market
Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/u-s-biosimilars-market-100990
Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.
The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others. In 2018, the autoimmune diseases held a market share of 92.0%. The segment is anticipated to remain in the leading position the U.S. biosimilars market during the forecast period. Factors like increasing adoption of biosimilars, rise in the prevalence of autoimmune diseases, and availability of limited drugs are likely to boost the segment. The Centers of Disease Control and Prevention declared that approximately 26% adults are estimated to have arthritis by 2040. This in turn, will increase the demand for biosimilars to treat arthritis. Moreover, treatment of cancer is expensive in the U.S. Combined with this, constant investments in research and development and rise in the adoption of sedentary lifestyle are projected to favor growth of the cancer segment throughout the forecast period in the U.S.
Detailed Table of Content:
1 U.S. Biosimilars Market Overview
1.1 U.S. Biosimilars Product Overview
1.2 U.S. Biosimilars Market Segment by Type
1.3 Global U.S. Biosimilars Market Size by Type (2015-2027)
1.3.1 Global U.S. Biosimilars Market Size Overview by Type (2015-2027)
1.3.2 Global U.S. Biosimilars Historic Market Size Review by Type (2015-2021)
126.96.36.199 Global U.S. Biosimilars Sales Market Share Breakdown by Type (2015-2027)
188.8.131.52 Global U.S. Biosimilars Market Share Breakdown by Type (2015-2027)
184.108.40.206 Global U.S. Biosimilars Average Selling Price (ASP) by Type (2015-2027)
1.3.3 Global U.S. Biosimilars Market Size Forecast by Type (2021-2027)
220.127.116.11 Global U.S. Biosimilars Sales Market Share Breakdown by Application (2021-2027)
18.104.22.168 Global U.S. Biosimilars Revenue Market Share Breakdown by Application (2021-2027)
22.214.171.124 Global U.S. Biosimilars Average Selling Price (ASP) by Application (2021-2027)
1.4 Key Regions Market Size Segment by Type (2015-2021)
1.4.1 North America U.S. Biosimilars Sales Breakdown by Type (2015-2027)
1.4.2 Europe U.S. Biosimilars Sales Breakdown by Type (2015-2027)
1.4.3 Asia-Pacific U.S. Biosimilars Sales Breakdown by Type (2015-2027)
1.4.4 Latin America U.S. Biosimilars Sales Breakdown by Type (2015-2027)
1.4.5 Middle East and Africa U.S. Biosimilars Sales Breakdown by Type (2015-2027)
2 Global U.S. Biosimilars Market Competition by Company
2.1 Global Top Players by U.S. Biosimilars Sales (2015-2021)
2.2 Global Top Players by U.S. Biosimilars Revenue (2015-2021)
2.3 Global Top Players U.S. Biosimilars Average Selling Price (ASP) (2015-2021)
2.4 Global Top Company U.S. Biosimilars Manufacturing Base Distribution, Sales Area, Product Type
2.5 U.S. Biosimilars Market Competitive Situation and Trends
2.5.1 U.S. Biosimilars Market Growth Rate (2015-2021)
2.5.2 Global 5 and 10 Largest Company by U.S. Biosimilars Sales and Revenue in 2019
2.6 Global Top Company by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in U.S. Biosimilars as of 2019)
2.7 Date of Key Company Enter into U.S. Biosimilars Market
2.8 Key Company U.S. Biosimilars Product Offered
2.9 Mergers and Acquisitions, Expansion
3 Global U.S. Biosimilars Status and Outlook by Region (2015-2027)
3.1 Global U.S. Biosimilars Market Size and CAGR by Region: 2015 VS 2021 VS 2027
3.2 Global U.S. Biosimilars Market Size Market Share by Region (2015-2021)
3.2.1 Global U.S. Biosimilars Sales Market Share by Region (2015-2021)
3.2.2 Global U.S. Biosimilars Revenue Market Share by Region (2015-2021)
3.2.3 Global U.S. Biosimilars Sales, Revenue, Price and Gross Margin (2015-2021)
3.3 Global U.S. Biosimilars Market Size Market Share by Region (2021-2027)
3.3.1 Global U.S. Biosimilars Sales Market Share by Region (2021-2027)
3.3.2 Global U.S. Biosimilars Revenue Market Share by Region (2021-2027)
3.3.3 Global U.S. Biosimilars Sales, Revenue, Price and Gross Margin (2021-2027)
3.4 North America U.S. Biosimilars Market Size By Growth (2015-2027)
3.4.1 North America U.S. Biosimilars Revenue By Growth (2015-2027)
3.4.2 North America U.S. Biosimilars Sales By Growth (2015-2027)
3.5 Asia-Pacific U.S. Biosimilars Market Size By Growth (2015-2027)
3.5.1 Asia-Pacific U.S. Biosimilars Revenue By Growth (2015-2027)
3.5.2 Asia-Pacific U.S. Biosimilars Sales By Growth (2015-2027)
For more information in the analysis of this report, visit:https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990
- Extensive product offerings
- Customer research services
- Robust research methodology
- Comprehensive reports
- Latest technological developments
- Value chain analysis
- Potential U.S. Biosimilars Market opportunities
- Growth dynamics
- Quality assurance
- Post-sales support
- Regular report updates
Reasons to Purchase this Report:
- Comprehensive analysis of the U.S. Biosimilars Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245